,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2014-01-14 04:00:00,Boston Scientific's third quarter 2014 adjusted EPS of $0.20 exceeded the year-ago figure by 17.6% but coincided with the Zacks Consensus Estimate and the upper end of the company's adjusted EPS guidance range of $0.18 $0.20.,0.856303870677948,0.08201378583908081,0.06168229877948761,positive,0.7742900848388672
1,2014-01-14 04:00:00,Revenues went up 7% at CER to $1.846 billion and also exceeded the Zacks Consensus Estimate.,0.9572902321815491,0.023823332041502,0.01888638362288475,positive,0.933466911315918
2,2014-01-14 04:00:00,The top line also came in well within the guided range.,0.7670770883560181,0.045218948274850845,0.18770389258861542,positive,0.7218581438064575
3,2014-01-14 04:00:00,The improvement in the core segments in the third quarter is encouraging and the increased guidance indicates that this growth is sustainable.,0.9507230520248413,0.015800874680280685,0.0334760881960392,positive,0.9349221587181091
4,2014-01-14 04:00:00,We are also optimistic about the recent update on the company's growth objective.,0.7894429564476013,0.013596374541521072,0.19696062803268433,positive,0.7758466005325317
5,2014-01-14 04:00:00,"The company is focusing on strategic initiatives like portfolio expansion, restructuring initiatives which include the 2014 restructuring plan, focus on emerging markets and share repurchases.",0.3513842225074768,0.007403689436614513,0.6412121653556824,neutral,0.3439805209636688
6,2014-01-14 04:00:00,"Yet, margin trend, currency headwinds and fierce competition in this sector continue to pose challenges.",0.23350894451141357,0.352919340133667,0.4135717451572418,neutral,-0.11941039562225342
7,2014-01-14 04:00:00,"Hence, we are Neutral on the stock.",0.02254662662744522,0.031156478449702263,0.9462969303131104,neutral,-0.008609851822257042
8,2014-01-14 04:00:00,"Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation (BSX) is a manufacturer of medical devices and products used in various interventional medical specialties worldwide.",0.07091093808412552,0.004457774572074413,0.9246312379837036,neutral,0.06645316630601883
9,2014-01-14 04:00:00,The company has adopted the organic as well as inorganic routes for success.,0.49617597460746765,0.008503222838044167,0.4953208267688751,positive,0.48767274618148804
10,2014-01-14 04:00:00,"Effective Jan 1, 2013, Boston Scientific made some changes in its reporting segments in order to reorganize its business from geographic and regional to fully operationalized global business units.",0.27982571721076965,0.010632130317389965,0.7095422148704529,neutral,0.2691935896873474
11,2014-01-14 04:00:00,"As a result, the company currently has three new global reportable segments consisting of Cardiovascular, Rhythm Management and MedSurg.",0.11208375543355942,0.005193181801587343,0.8827230334281921,neutral,0.10689057409763336
12,2014-01-14 04:00:00,The company is one of the leading players in the interventional cardiology market with its coronary stent product offerings.,0.6578083634376526,0.010220449417829514,0.3319711983203888,positive,0.6475878953933716
13,2014-01-14 04:00:00,Boston Scientific markets next-generation internally-developed and self-manufactured Promus Element everolimus-eluting stent platform in all major markets worldwide as well as Taxus paclitaxel-eluting stent line including the third-generation Taxus Element stent system.,0.11058901995420456,0.004606591537594795,0.884804368019104,neutral,0.10598243027925491
14,2014-01-14 04:00:00,"The company also markets balloon catheters, rotational atherectomy systems, guide wires, guide catheters, embolic protection devices, and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures, as well as intravascular ultrasound (IVUS) imaging systems.",0.03612693399190903,0.005376360844820738,0.9584966897964478,neutral,0.030750572681427002
15,2014-01-14 04:00:00,"Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities.",0.053896281868219376,0.004631817806512117,0.9414719343185425,neutral,0.049264464527368546
16,2014-01-14 04:00:00,"The portfolio includes implantable cardioverter defibrillator (ICD) systems, cardiac resynchronization therapy defibrillator (CRT-D) systems and cardiac resynchronization therapy pacemaker (CRT-P) systems.",0.024265751242637634,0.0052172536961734295,0.9705169796943665,neutral,0.019048497080802917
17,2014-01-14 04:00:00,Want the latest recommendations from Zacks Investment Research?,0.03539300337433815,0.011573811061680317,0.9530332088470459,neutral,0.023819193243980408
18,2014-01-14 04:00:00,"Today, you can download 7 Best Stocks for the Next 30 Days.",0.05069372057914734,0.007019792217761278,0.9422864317893982,neutral,0.04367392882704735
19,2014-01-14 04:00:00,"Click to get this free report

To read this article on Zacks.com click here.",0.020684564486145973,0.03315984085202217,0.9461556077003479,neutral,-0.012475276365876198
20,2014-01-14 04:00:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.015637893229722977,0.9741575717926025,neutral,-0.0054333265870809555
